|
|
Article: Athenagen Gains New AD Platform Via Zapaq Merger.(Company overview)
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Adding a new Alzheimer's disease platform to its portfolio, Athenagen Inc. agreed to merge with Zapaq Inc., a 5-year-old company focused on beta-secretase inhibitors.
Both companies are privately held, and the value of the transaction was not disclosed.
Based in Oklahoma City, Zapaq was founded in 2001 by Jordan Tang, of the Oklahoma Medical Research Foundation, and Arun Ghosh, a professor at Purdue University.
Tang discovered the aspartic protease beta-secretase in 2000, and details of the discovery then were published in Proceedings of the National Academy of Sciences. Beta-secretase is an enzyme critical to beta ...